Skip to content

The curative effect evaluation for Yi-Qi Yang-Yin Huo-Xue prescription in treatment of the high risk population of hepatitis B cirrhosis with chronic kidney injury

The curative effect evaluation for Yi-Qi Yang-Yin Huo-Xue prescription in treatment of the high risk population of hepatitis B cirrhosis with chronic kidney injury

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026984
Enrollment
Unknown
Registered
2019-10-27
Start date
2018-06-01
Completion date
Unknown
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

Sponsors

Beijing Ditan Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meet the Western medicine diagnosis standard of high risk population with hepatitis B cirrhosis complicated with CKD; 2. Men or women aged 18-65; 3. Meet the syndrome of traditional Chinese medicine belongs to Yin deficiency of liver and kidney, Qi deficiency and blood stasis. 4. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who are allergy to the applied components of traditional Chinese medicine; 2. The researchers determined that antiviral treatment should be carried out while the patients themselves did not; 3. Cirrhosis with AKI or HRS; 4. Patients with other hepatophilic virus infection or with autoimmune liver disease, primary biliary cirrhosis, hereditary metabolic liver disease, unrequited alcoholic liver disease and liver transplantation; 5. Uncontrolled hypertension, diabetes, malignant tumor and other serious diseases; 6. Previous renal calculus, chronic glomerulonephritis, nephrotic syndrome, IgA nephropathy, systemic lupus erythematosus, nephrotoxic drug-related renal damage and other kidney diseases; 7. Baseline GFR < 60 ml / (min / 1.73 m2); 8. Women within pregnancy and lactation period; 9. Patients who cannot cooperate.

Design outcomes

Primary

MeasureTime frame
Incidence of CKD;

Secondary

MeasureTime frame
Incidence of hepatorenal syndrome;Child Pugh and MELD scores;TCM syndrome scores;

Countries

China

Contacts

Public ContactXianbo Wang

Beijing Ditan Hospital, Capital Medical University

wangxianbo638@163.com+86 010-84322301

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026